In lung cancer patients who responded to PD-1/PD-L1 blocking, the expression of CD69 was upregulated, indicating that CD69 expression levels can effectively predict cancer response to PD-1/PD-L1 blockade immunotherapy46. Here, CD69 is linked to cancer.